The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06222164

Enrollment

2000

Registered

2024-01-24

Start date

2024-03-30

Completion date

2027-06-30

Last updated

2025-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic Diseases

Keywords

residual samples hematologic diseases

Brief summary

Acquire residual human specimens and/or samples from patient samples which were sent for testing at LabPMM, LLC for Clinical Research

Detailed description

Residual specimen/sample collection study where peripheral blood (PB), bone marrow (BM), genomic (gDNA), and/or formalin-fixed paraffin-embedded tissue (FFPE) specimens/samples are obtained from patient samples sent to LabPMM, LLC for clinical testing. Samples may be used for Clinical Research at LabPMM, LLC or at partner institutions

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Specimen/sample, peripheral blood (PB), bone marrow (BM), genomic DNA (gDNA) and/or formalin-fixed paraffin-embedded tissue (FFPE) from patients whose specimens/samples have been sent to LabPMM for clinical testing 2. Donor Age ≥ 18 years

Exclusion criteria

1. Sample/specimen has been obtained from a third-party vendor with a Materials Transfer Agreement (MTA) on file with LabPMM 2. The specimens/samples have previously been enrolled in a clinical study

Design outcomes

Primary

Measure	Time frame	Description
Enrollment	3 years	N=2000

Countries

United States

Contacts

Primary ContactAndrew Schut

aschut@invivoscribe.com+1 858.224.6600

Outcome results